US Newborn Screening Market Outlook 2020
The US Newborn Screening market is set to witness several developments in near future. In the new report entitled, “US Newborn Screening Market Outlook 2020” the market has been separately studied under tests used for screening, and technologies supporting the diagnosis.
93% of the newborns are screened for various disorders under the newborn screening test in the US. The government is taking various measures to improve the quality and efficiency of these tests. Furthermore, the governments of various states are also engaged in expanding the panel of the tests.
Blood spot test is the most widely performed newborn screening test, followed by hearing screening and Critical Congenital Heart Disease (CCHD) Newborn Screening respectively. The screening technologies used for these tests include tandem mass spectrometry, immunoassays, pulse oximetry, DNA assays and electrophoresis. Immunoassay is the most extensively used technology for newborn screening. The large share of this technology is attributed to the fact that it is a part of primary screening tests for the newborn. Hence, these tests would always witness higher demand.
The report covers developments in the market occurring over the last two years, drivers and challenges controlling the market, and competitive landscape showing prominent players. Factors such as government support through funds, growing awareness, technological advancements and surging genetic disorders are fuelling the growth. On the other hand, lack of uniform regulatory policies in the country and delays in hospital administration are major hurdles of the market.
The study includes prudent analysis of the market size (tests and technologies) for 2014, and forecast till 2020. At the competitive forefront, research has been done at each player including their financials, key products, developments and SWOT analysis. In brief, study presented in the report is likely to generate interest among the potential investors.
93% of the newborns are screened for various disorders under the newborn screening test in the US. The government is taking various measures to improve the quality and efficiency of these tests. Furthermore, the governments of various states are also engaged in expanding the panel of the tests.
Blood spot test is the most widely performed newborn screening test, followed by hearing screening and Critical Congenital Heart Disease (CCHD) Newborn Screening respectively. The screening technologies used for these tests include tandem mass spectrometry, immunoassays, pulse oximetry, DNA assays and electrophoresis. Immunoassay is the most extensively used technology for newborn screening. The large share of this technology is attributed to the fact that it is a part of primary screening tests for the newborn. Hence, these tests would always witness higher demand.
The report covers developments in the market occurring over the last two years, drivers and challenges controlling the market, and competitive landscape showing prominent players. Factors such as government support through funds, growing awareness, technological advancements and surging genetic disorders are fuelling the growth. On the other hand, lack of uniform regulatory policies in the country and delays in hospital administration are major hurdles of the market.
The study includes prudent analysis of the market size (tests and technologies) for 2014, and forecast till 2020. At the competitive forefront, research has been done at each player including their financials, key products, developments and SWOT analysis. In brief, study presented in the report is likely to generate interest among the potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. NEWBORN SCREENING - AN INTRODUCTION
4. DRIVERS AND CHALLENGES
4.1 Drivers
4.1.1 Increased Awareness Due to Government Initiatives
4.1.2 Rising Chromosomal Abnormalities in Infants
4.1.3 Funding Aiding the Growth of Newborn Screening
4.2 Challenges
4.2.1 Lack of Hospital Infrastructure Proving Dangerous for Newborns
4.2.2 Unclear Regulatory Policies
5. US NEWBORN SCREENING MARKET OVERVIEW
6. MARKET SEGMENTATION BY TECHNOLOGY
6.1 Introduction
6.1.1 Enzymes and Immunoassays
6.1.2 Hearing Screening
6.1.3 Tandem Mass Spectrometry
6.1.4 Pulse Oximetry
6.1.5 DNA Based Assays
6.1.6 Electrophoresis
7. TRENDS AND DEVELOPMENTS
7.1 Newborn Screening Test Recommended for Pompe’s Disease
7.2 Next Generation Sequencing Foraying into Newborn Screening
8. COMPETITIVE ASSESSMENT
8.1 Perkin Elmer
8.2 Waters Corporation
8.3 Natus Medical
8.4 Agilent Technologies Inc.
2. RESEARCH METHODOLOGY
3. NEWBORN SCREENING - AN INTRODUCTION
4. DRIVERS AND CHALLENGES
4.1 Drivers
4.1.1 Increased Awareness Due to Government Initiatives
4.1.2 Rising Chromosomal Abnormalities in Infants
4.1.3 Funding Aiding the Growth of Newborn Screening
4.2 Challenges
4.2.1 Lack of Hospital Infrastructure Proving Dangerous for Newborns
4.2.2 Unclear Regulatory Policies
5. US NEWBORN SCREENING MARKET OVERVIEW
6. MARKET SEGMENTATION BY TECHNOLOGY
6.1 Introduction
6.1.1 Enzymes and Immunoassays
6.1.2 Hearing Screening
6.1.3 Tandem Mass Spectrometry
6.1.4 Pulse Oximetry
6.1.5 DNA Based Assays
6.1.6 Electrophoresis
7. TRENDS AND DEVELOPMENTS
7.1 Newborn Screening Test Recommended for Pompe’s Disease
7.2 Next Generation Sequencing Foraying into Newborn Screening
8. COMPETITIVE ASSESSMENT
8.1 Perkin Elmer
8.2 Waters Corporation
8.3 Natus Medical
8.4 Agilent Technologies Inc.
LIST OF FIGURES:
Figure 5-1: Newborn Screening Test Market (Million US$), 2014 & 2020
Figure 5-2: Newborn Screening Technology Market (Million US$), 2014-2020
Figure 6-1: US Newborn Screening Market by Technology (%), 2014
Figure 6-2: Enzymes and Immunoassays Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-3: Hearing Screen Technology Market for Newborn Screening (Million US$), 2014 &2020
Figure 6-4: Tandem Mass Spectrometry Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-5: Pulse Oximetry Technology Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-6: DNA-Based Assays Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-7: Electrophoresis Market for Newborn Screening (Million US$), 2014 & 2020
Figure 5-1: Newborn Screening Test Market (Million US$), 2014 & 2020
Figure 5-2: Newborn Screening Technology Market (Million US$), 2014-2020
Figure 6-1: US Newborn Screening Market by Technology (%), 2014
Figure 6-2: Enzymes and Immunoassays Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-3: Hearing Screen Technology Market for Newborn Screening (Million US$), 2014 &2020
Figure 6-4: Tandem Mass Spectrometry Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-5: Pulse Oximetry Technology Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-6: DNA-Based Assays Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-7: Electrophoresis Market for Newborn Screening (Million US$), 2014 & 2020
LIST OF TABLES:
Table 5-1: Number of Conditions Tested & Cost by States (2014)
Table 5-2: Common Misconceptions Held by the Public and the Clinical Facts
Table 8-1: Perkin Elmer - Key Financials (Million US$), 2012-2014
Table 8-2: Waters Corporation - Key Financials (Million US$), 2012-2014
Table 8-3: Natus Medical - Key Financials (Million US$), 2012-2014
Table 8-4: Agilent - Key Financials (Million US$), 2013-2015
Table 5-1: Number of Conditions Tested & Cost by States (2014)
Table 5-2: Common Misconceptions Held by the Public and the Clinical Facts
Table 8-1: Perkin Elmer - Key Financials (Million US$), 2012-2014
Table 8-2: Waters Corporation - Key Financials (Million US$), 2012-2014
Table 8-3: Natus Medical - Key Financials (Million US$), 2012-2014
Table 8-4: Agilent - Key Financials (Million US$), 2013-2015
